- API
Botswana Combination Prevention Project (BCPP) - Public Release Data
data.cdc.gov | Last Updated 2022-05-24T12:45:57.000ZThe Botswana Combination Prevention Project (BCPP) was a research project conducted by the Botswana Ministry of Health (MOH), Harvard School of Public Health/Botswana Harvard AIDS Institute Partnership (BHP), and the U.S. Centers for Disease Control and Prevention (CDC). BCPP was a community randomized trial that examined the impact of prevention interventions on HIV incidence in 15 intervention and 15 control communities. The interventions included extensive HIV testing, linkage to care, and universal treatment services. To reduce HIV incidence in the intervention communities, the UNAIDS 90-90-90 goals were used: 90% of HIV-positive persons know their status; 90% of persons who know status are to be on ART; 90% of persons on ART are to be virally suppressed. The BCPP study is composed of 2 interlocking protocols: Evaluation Protocol and Intervention Protocol. The Evaluation Protocol of the BCPP evaluated the primary endpoint (HIV incidence), as well as some key related secondary endpoints. This protocol focused on the Baseline Household Survey; the HIV Incidence Cohort; and an End of Study Survey. The Intervention Protocol of the BCPP implemented the combination prevention (CP) intervention package in CPCs and measures the uptake of these interventions (expanded HIV testing and counselling, strengthened male circumcision, and expanded HIV Care and Treatment).
- API
Vaccine Hesitancy for COVID-19: County and local estimates
data.cdc.gov | Last Updated 2021-06-17T20:27:47.000ZDue to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.. PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p
- API
NNDSS - TABLE 1JJ. Tuberculosis to Tularemia
data.cdc.gov | Last Updated 2022-01-12T18:38:56.000ZNNDSS - TABLE 1JJ. Tuberculosis to Tularemia – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
- API
NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus
data.cdc.gov | Last Updated 2022-01-12T18:39:21.000ZNNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). § Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers". NNDSS was updated beginning in 2015 to receive data for each of the viral hemorrhagic fevers listed.
- API
COVID-19 County Hesitancy
data.cdc.gov | Last Updated 2021-06-17T20:00:41.000ZThis map shows estimates of COVID-19 vaccine hesitancy rates using data from the U.S. Census Bureau’s Household Pulse Survey (HPS). We estimate hesitancy rates in two steps. First, we estimate hesitancy rates at the state level using the HPS for the collection period March 3, 2021 – March 15, 2021, which is referred to as Week 26. Then, we utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center. PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. We use the HPS survey question, “Once a vaccine to prevent COVID-19 is available to you, would you…get a vaccine?”, which provides the following options: 1) “definitely get a vaccine”; 2) “probably get a vaccine”; 3) “probably not get a vaccine”; 4) “definitely not get a vaccine”. COVID-19 vaccine hesitancy was defined as follows: hesitancy: includes survey responses indicating that they would “probably not” or “definitely not” receive a COVID-19 vaccine when available. strong hesitancy: include only survey responses indicating that they would “definitely not” receive a COVID-19 vaccine when available. Full methodology for estimates of COVID-19 vaccine hesitancy is available here. Demographic data were obtained from the 2019 American Community Survey (ACS) 5-year estimates. Overall social vulnerability index was obtained from the 2018 CDC Social Vulnerability Index. The CDC's Social Vulnerability Index (SVI) summarizes the extent to which a community is socially vulnerable to disaster. The factors considered in developing the SVI include economic data as well as data regarding education, family characteristics, housing language ability, ethnicity, and vehicle access. SVI values range from 0 (least vulnerable) to 1 (most vulnerable). The SVI can also be categorized as follows: Very Low (0.0-0.19), Low (0.20-0.39); Moderate (0.40-0.59); High (0.60-0.79); Very High (0.80-1.0). The ability to handle a COVID-19 outbreak was obtained from the Surgo Covid-19 Vaccine Coverage Index (CVAC). The Covid-19 Vaccine Coverage (CVAC) Index measures how well a community may be able to handle the repercussions of a COVID-19 outbreak. CVAC is based on a community's access to health care, affordable housing, transportation, childcare, or safe and secure employment. CVAC Index values range from 0 (least vulnerable) to 1 (most vulnerable). The CVAC Index can also be categorized as follows: Very Low (0.0-0.19), Low (0.20-0.39); Moderate (0.40-0.59); High (0.60-0.79); Very High (0.80-1.0). The percent of adults (18+) in the population who are fully vaccinated was obtained from the CDC COVID-19 Data Tracker, Integrated County View as of March 30, 2021. Vaccination rate data may not be available for all states. Systematic missing data in some states may result in vaccination coverage by county appearing artificially low.
- API
Impaired Driving Death Rate, by Age and Gender, 2012 & 2014, Region 6 - Dallas
data.cdc.gov | Last Updated 2016-09-14T15:04:53.000ZRate of deaths by age/gender (per 100,000 population) for people killed in crashes involving a driver with BAC =>0.08%, 2012, 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File. Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.
- API
Early Model-based Provisional Estimates of Drug Overdose, Suicide, and Transportation-related Deaths
data.cdc.gov | Last Updated 2022-03-30T16:02:45.000ZThis dataset provides model-based provisional estimates of the weekly numbers of drug overdose, suicide, and transportation-related deaths using “nowcasting” methods to account for the normal lag between the occurrence and reporting of these deaths. Estimates less than 10 are suppressed. These early model-based provisional estimates were generated using a multi-stage hierarchical Bayesian modeling process to generate smoothed estimates of the weekly numbers of death, accounting for reporting lags. These estimates are based on several assumptions about how the reporting lags have changed in recent months across different jurisdictions, and the resulting estimates differ from other sources of provisional mortality data. For now, these estimates should be considered highly uncertain until further evaluations can be done to determine the validity of these assumptions about timeliness. The true patterns in reporting lags will not be known until data are finalized, typically 11–12 months after the end of the calendar year. Importantly, these estimates are not a replacement for monthly provisional drug overdose death counts, or quarterly provisional mortality estimates. For more detail about the nowcasting methods and models, see: Rossen LM, Hedegaard H, Warner M, Ahmad FB, Sutton PD. Early provisional estimates of drug overdose, suicide, and transportation-related deaths: Nowcasting methods to account for reporting lags. Vital Statistics Rapid Release; no 11. Hyattsville, MD: National Center for Health Statistics. February 2021. DOI: https://doi.org/10.15620/ cdc:101132
- API
Healthy People 2020 Final Progress Table
data.cdc.gov | Last Updated 2023-08-23T19:39:25.000Z[1] Status is determined using the baseline, final, and target value. The statuses used in Healthy People 2020 were: 1 - Target met or exceeded—One of the following applies: (i) At baseline, the target was not met or exceeded, and the most recent value was equal to or exceeded the target. (The percentage of targeted change achieved was equal to or greater than 100%.); (ii) The baseline and most recent values were equal to or exceeded the target. (The percentage of targeted change achieved was not assessed.) 2 - Improved—One of the following applies: (i) Movement was toward the target, standard errors were available, and the percentage of targeted change achieved was statistically significant; (ii) Movement was toward the target, standard errors were not available, and the objective had achieved 10% or more of the targeted change. 3 - Little or no detectable change—One of the following applies: (i) Movement was toward the target, standard errors were available, and the percentage of targeted change achieved was not statistically significant; (ii) Movement was toward the target, standard errors were not available, and the objective had achieved less than 10% of the targeted change; (iii) Movement was away from the baseline and target, standard errors were available, and the percent change relative to the baseline was not statistically significant; (iv) Movement was away from the baseline and target, standard errors were not available, and the objective had moved less than 10% relative to the baseline; (v) No change was observed between the baseline and the final data point. 4 - Got worse—One of the following applies: (i) Movement was away from the baseline and target, standard errors were available, and the percent change relative to the baseline was statistically significant; (ii) Movement was away from the baseline and target, standard errors were not available, and the objective had moved 10% or more relative to the baseline. 5 - Baseline only—The objective only had one data point, so progress toward target attainment could not be assessed. Note that if additional data points did not meet the criteria for statistical reliability, data quality, or confidentiality, the objective was categorized as baseline only. 6 - Informational—A target was not set for this objective, so progress toward target attainment could not be assessed. [2] The final value is generally based on data available on the Healthy People 2020 website as of January 2020. For objectives that are continuing into Healthy People 2030, more recent data are available on the Healthy People 2030 website: https://health.gov/healthypeople. [3] For objectives that moved toward their targets, movement toward the target was measured as the percentage of targeted change achieved (unless the target was already met or exceeded at baseline): Percentage of targeted change achieved = (Final value - Baseline value) / (HP2020 target - Baseline value) * 100 [4] For objectives that were not improving, did not meet or exceed their targets, and did not move towards their targets, movement away from the baseline was measured as the magnitude of the percent change from baseline: Magnitude of percent change from baseline = |Final value - Baseline value| / Baseline value * 100 [5] Statistical significance was tested when the objective had a target, at least two data points (of unequal value), and available standard errors of the data. A normal distribution was assumed. All available digits were used to test statistical significance. Statistical significance of the percentage of targeted change achieved or the magnitude of the percentage change from baseline was assessed at the 0.05 level using a normal one-sided test. [6] For more information on the Healthy People 2020 methodology for measuring progress toward target attainment and the elimination of health disparities, see: Healthy People Statistical Notes, no 27; available from: https://www.cdc.gov/nchs/data/sta
- API
NNDSS - TABLE 1AA. Poliovirus infection, nonparalytic to Psittacosis
data.cdc.gov | Last Updated 2022-01-12T18:37:35.000ZNNDSS - TABLE 1AA. Poliovirus infection, nonparalytic to Psittacosis - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
- API
NNDSS - TABLE 1Q. Hepatitis B, perinatal infection to Hepatitis C, acute, Probable
data.cdc.gov | Last Updated 2022-01-12T18:36:07.000ZNNDSS - TABLE 1Q. Hepatitis B, perinatal infection to Hepatitis C, acute, Probable - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). § For acute Hepatitis C, only confirmed cases were verified.